Hot on the heels of a recent FDA draft guidance on the topic, the EMA last week released a new concept paper which explains the regulator’s many, many concerns with the use of single-arm trials – concerns which any sponsor hoping to leverage a single-arm trial will have to successfully navigate.
Background and Context
Global regulators typically consider blinded, randomized controlled trials (RCTs) to be the gold standard of clinical trials.
Fill out the form to read the full article.
